The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Use a concentration of 10 µg/ml.
Use a concentration of 5 - 10 µg/ml.
Receptor-activated non-selective cation channel involved in detection of pain and possibly also in cold perception and inner ear function. Has a central role in the pain response to endogenous inflammatory mediators and to a diverse array of volatile irritants, such as mustard oil, garlic and acrolein, an irritant from tears gas and vehicule exhaust fumes. Acts also as a ionotropic cannabinoid receptor by being activated by delta(9)-tetrahydrocannabinol (THC), the psychoactive component of marijuana. Not involved in menthol sensation. May be a component for the mechanosensitive transduction channel of hair cells in inner ear, thereby participating in the perception of sounds. Probably operated by a phosphatidylinositol second messenger system.
Expressed at very low level. Expressed at very low level in human fibroblasts and at a moderate level in liposarcoma cells.
Belongs to the transient receptor (TC 1.A.4) family. Contains 15 ANK repeats.
ab62053, at 20µg/ml, staining TRPA1 in Formalin/PFA Fixed Paraffin-Embedded Human DRG tissue cells by Immunohistochemistry.
Immunohistochemistry (Frozen sections) - Anti-TRPA1 antibody (ab62053)Image courtesy of an anonymous Abreview.
ab62053 staining TRPA1 in murine skin tissue by Immunohistochemistry (Frozen sections). Tissue was fixed in methanol, permeabilized with 0.4% Triton X-100, blocked using 10% serum for 30 minutes at 25°C and then incubated with ab62053 at a 1/100 dilution for 16 hours at 4°C. The secondary used was an Alexa-Fluor 594 conjugated goat anti-rabbit polyclonal used at a 1/500 dilution.
Lowin T et al. Anti-inflammatory effects of N-acylethanolamines in rheumatoid arthritis synovial cells are mediated by TRPV1 and TRPA1 in a COX-2 dependent manner. Arthritis Res Ther17:321 (2015).
Read more (PubMed: 26567045) »
Denda M et al. Topical application of TRPA1 agonists and brief cold exposure accelerate skin permeability barrier recovery. J Invest Dermatol130:1942-5 (2010).
Read more (PubMed: 20182443) »